UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

British journal of cancer, 2013-12, Vol.109 (12), p.2959-2964

2013

Volltextzugriff (PDF)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

Annals of oncology, 2013-03, Vol.24 (3), p.640-647

2013

Volltextzugriff (PDF)

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of oncology, 2017-06, Vol.28 (6), p.1309-1315

2017

Volltextzugriff (PDF)

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

Annals of oncology, 2018-01, Vol.29 (1), p.170-177

2018

Volltextzugriff (PDF)

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

British journal of cancer, 2012-11, Vol.107 (11), p.1892-1900

2012

Volltextzugriff (PDF)

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of oncology, 2019-11, Vol.30 (11), p.1846-1846

2019

Volltextzugriff (PDF)

Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma

Annals of oncology, 2018-10, Vol.29, p.viii734-viii735

2018

Volltextzugriff (PDF)

Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2− breast cancer patients

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.S4-S4-3

2012

Volltextzugriff (PDF)

7OPAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

Annals of oncology, 2019-05, Vol.30, p.iii3-iii3

2019

Volltextzugriff (PDF)

LBA43Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Prädiktive Biomarker beim ER+/HER2 - Mammakarzinom - Diskrepanz zwischen S3-Leitlinie, AGO-Empfehlung und St.-Gallen-Expertenmeinung

Senologie (Stuttgart), 2013-03, Vol.10 (1), p.34-38

2013

Volltextzugriff (PDF)

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of oncology, 2019-11, Vol.30 (11), p.1846

2019

Volltextzugriff (PDF)

Abstract P2-11-06: Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy - A GEICAM/ 9906 sub-study

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-11-06

2013

Volltextzugriff (PDF)

Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM/9906 trial

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P2-P2-10-11

2012

Volltextzugriff (PDF)

P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2−Negative Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-06-26

2011

Volltextzugriff (PDF)

Circulating microRNAs associated with early relapse in early-stage NSCLC

Pneumologie (Stuttgart, Germany), 2012, Vol.66 (6)

2012

Volltextzugriff (PDF)

Les fronts intérieurs européens: L’arrière en guerre (1914-1920)

2018

Volltextzugriff (PDF)

Legacy and Emerging Per- and Polyfluoroalkyl Substances: Analytical Techniques, Environmental Fate, and Health Effects

International journal of molecular sciences, 2021-01, Vol.22 (3), p.995

2021

Volltextzugriff (PDF)

Faux bruits, rumeurs et fake news

2021

Volltextzugriff (PDF)

Neutrinoless double- β decay from an effective field theory for heavy nuclei

Physical review. C, 2022-09, Vol.106 (3), Article 034309

2022

Volltextzugriff (PDF)

Two-neutrino ββ decay of 136Xe to the first excited 0+ state in 136Ba

Physics letters. B, 2023-03, Vol.838, p.137689, Article 137689

2023

Volltextzugriff (PDF)

Personality and Saving Behavior Among Older Adults

The Journal of consumer affairs, 2019-06, Vol.53 (2), p.488-519

2019

Volltextzugriff (PDF)

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2466-2476

2020

Volltextzugriff (PDF)

Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers

Nature communications, 2023-04, Vol.14 (1), p.2314-2314, Article 2314

2023

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma

Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2− breast cancer patients

7OPAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

LBA43Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma

Prädiktive Biomarker beim ER+/HER2 - Mammakarzinom - Diskrepanz zwischen S3-Leitlinie, AGO-Empfehlung und St.-Gallen-Expertenmeinung

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Abstract P2-11-06: Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy - A GEICAM/ 9906 sub-study

Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM/9906 trial

P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2−Negative Breast Cancer

Circulating microRNAs associated with early relapse in early-stage NSCLC

Les fronts intérieurs européens: L’arrière en guerre (1914-1920)

Legacy and Emerging Per- and Polyfluoroalkyl Substances: Analytical Techniques, Environmental Fate, and Health Effects

Faux bruits, rumeurs et fake news

Neutrinoless double- β decay from an effective field theory for heavy nuclei

Two-neutrino ββ decay of 136Xe to the first excited 0+ state in 136Ba

Personality and Saving Behavior Among Older Adults

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers

Suchergebnisse filtern